COMLEX Level 2 Practice Exam 2026 - Free Comprehensive Osteopathic Medical Licensing Questions and Study Guide

The choice indicating teriparatide usage as a condition likely leading to hypercalcemia is based on the mechanism of action of this medication. Teriparatide is a recombinant form of parathyroid hormone used primarily in the treatment of osteoporosis. It stimulates bone formation by increasing osteoblast activity. However, it can also lead to increased serum calcium levels through its effects on bone resorption and enhanced renal tubular reabsorption of calcium.

Under certain circumstances, particularly with excessive dosing or prolonged use, teriparatide might cause significant increases in serum calcium, resulting in hypercalcemia. This effect is particularly relevant when considering the biochemical influences of parathyroid hormone on calcium metabolism in the body, as it directly raises calcium levels in the bloodstream.

In contrast, conditions like rheumatoid arthritis, osteoporosis, and hypoparathyroidism do not typically cause hypercalcemia. Rheumatoid arthritis is an autoimmune condition associated with joint inflammation rather than disturbances in calcium metabolism. Osteoporosis primarily results from a decrease in bone density and does not inherently elevate calcium levels. Hypoparathyroidism, characterized by insufficient parathyroid hormone secretion, would lead to hypocalcemia, not hypercalcemia, due to decreased calcium mobilization from bones and reduced renal absorption of calcium